Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, Doz F, Moreno L, Ruggiero A, Gerber NU, Fagioli F, Hingorani P, Melcón SG, Slepetis R, Chen N, le Bruchec Y, Simcock M, Vassal G

Open source

DOI: 10.1016/j.ejca.2020.04.031
Published: 2020 Aug
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2020.04.031,
  title = {Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.},
  author = {Amoroso L and Castel V and Bisogno G and Casanova M and Marquez-Vega C and Chisholm JC and Doz F and Moreno L and Ruggiero A and Gerber NU and Fagioli F and Hingorani P and Melcón SG and Slepetis R and Chen N and le Bruchec Y and Simcock M and Vassal G},
  year = {2020},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2020.04.031},
  url = {https://doi.org/10.1016/j.ejca.2020.04.031}
}

RIS

TY  - JOUR
TI  - Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
AU  - Amoroso L
AU  - Castel V
AU  - Bisogno G
AU  - Casanova M
AU  - Marquez-Vega C
AU  - Chisholm JC
AU  - Doz F
AU  - Moreno L
AU  - Ruggiero A
AU  - Gerber NU
AU  - Fagioli F
AU  - Hingorani P
AU  - Melcón SG
AU  - Slepetis R
AU  - Chen N
AU  - le Bruchec Y
AU  - Simcock M
AU  - Vassal G
PY  - 2020
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2020.04.031
UR  - https://doi.org/10.1016/j.ejca.2020.04.031
ER  -

APA

L, A., V, C., G, B., M, C., C, M., JC, C., F, D., L, M., A, R., NU, G., F, F., P, H., SG, M., R, S., N, C., Y, L. B., M, S., & G, V. (2020). Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2020.04.031

Source records

pubmed · retrieved 2026-09-27T09:24:41.620Z